ZOLGENSMA

By: NOVARTIS AG

Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy ...


Logo Design and Free Alerts provided by Trademarks On Call, Inc.

Status Alert: On Tuesday, October 29, 2019, the status for the ZOLGENSMA mark changed to REGISTERED .

SPONSORED CONTENT - Services provided by law firm Classic Counsel, P.C.†
If your trademark has been registered for 5 years, it's time to file a renewal with the U.S. Patent and Trademark Office. A licensed trademark attorney can assist you with this renewal. To begin, call (240)744-4614 or start online:
On Monday, November 06, 2017, a U.S federal trademark application was filed for ZOLGENSMA by AveXis, Inc., 2275 Half Day Rd., Suite 200, Bannockburn, IL.

The USPTO has assigned the ZOLGENSMA mark the serial number 87673650. The ZOLGENSMA mark has been filed in the category Pharmaceutical Products.

The owner of the ZOLGENSMA mark is listed as NOVARTIS AG, CH-4002, BASEL. The correspondent for the ZOLGENSMA mark is Maury M. Tepper, III Tepper & Eyster, PLLC of 3724 BENSON DR, RALEIGH, NC 27609, UNITED STATES. If you have licensing, usage or other questions concerning the ZOLGENSMA mark, please contact the owner through the listed correspondent.

The description provided for the ZOLGENSMA mark is Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy ...
Word Mark: ZOLGENSMA
Status: REGISTERED
Status Date: 10/29/2019
Serial Number: 87673650
Filing Date: 11/06/2017
Registration Number: 5897769
Registration Date: 10/29/2019
Goods and Services: Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, or neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparation in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression
Type Of Mark: Trademark
Register Type: Principal
Published For Opposition Date: 05/15/2018
Current Owner: NOVARTIS AG
CH-4002
BASEL 4002
SWITZERLAND
Mark Description: Not Available
Mark Drawing Type: Not Available
Design Search: Not Available
Disclaimer: Not Available
Correspondent: Maury M. Tepper, III Tepper & Eyster, PLLC
3724 BENSON DR
RALEIGH, NC 27609
UNITED STATES
   

 

Class Information

International Class(es):005
US Class(es):006, 018, 044, 046, 051, 052
Primary Class:Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Class(es) Status:Active
First Use Anywhere: 06/10/2019
First Use In Commerce:06/10/2019
Retrieve Trademark Documents